Ozoralizumab  (Synonyms: ATN-103; PF-5230896)

Ozoralizumab (ATN-103) is an anti-TNFα humanized antibody. Ozoralizumab is a humanized trivalent nanobody compound that consists of two anti-human TNFα nanobodies and an anti-human serum albumin (HSA) nanobody. Ozoralizumab can be used in research of arthritis^[1].

VH-VH'-VH, trivalent

Human

TNFα & ALB

Ozoralizumab (ATN-103; 0-1000 pM; 48 h) has high TNFα-neutralizing potency in the L929 cell cytotoxicity assay with K_D values of 20.2 pM and 16.1 pM for human TNFα and monkey TNFα, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ozoralizumab (ATN-103; 1 mg/kg; s.c.; Tg197 human TNF transgenic mice) inhibits arthritis and reduces arthritis scores^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

7124  [NCBI] & 213  [NCBI]

P01375 & P02768

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

38.43 kDa

1167985-17-2

Liquid

Colorless to light yellow

[Ozoralizumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  VH-VH'-VH, trivalent

• 
  Immobilized Human TNF-alpha Protein (hFc Tag) can bind Ozoralizumab. The EC₅₀ for this effect is 62.82 ng/mL.

• [1]. Ishiwatari-Ogata C, et, al. Ozoralizumab, a Humanized Anti-TNFα NANOBODY® Compound, Exhibits Efficacy Not Only at the Onset of Arthritis in a Human TNF Transgenic Mouse but Also During Secondary Failure of Administration of an Anti-TNFα IgG. Front Immunol. 2022 Feb 22;13:853008.  [Content Brief]